Previous 10 | Next 10 |
Otonomy (OTIC) announces preclinical proof-of-concept results for OTO-825 at the ASGCT Annual Meeting. OTO-825 is an AAV-mediated gene therapy developed in collaboration with Applied Genetic Technologies Corporation (AGTC).The results demonstrate that a single administration of OTO-825 rescue...
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene &...
Otonomy, Inc. (OTIC) Q1 2021 Earnings Conference Call May 11, 2021, 16:30 ET Company Participants Robert Uhl - MD David Weber - President, CEO & Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowen and Company Charles Duncan - Cantor F...
Otonomy (OTIC): Q1 GAAP EPS of -$0.23 in-line.Revenue of $0.09M (-43.8% Y/Y) beats by $0.06M.Press Release For further details see: Otonomy EPS in-line, beats on revenue
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with prec...
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4...
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American So...
Gainers: [[OTIC]] +10.4%. [[ASRV]] +5.2%. [[ANGI]] +3.3%. [[HLIT]] +2.7%. [[GDS]] +2.7%.Losers: [[VNET]] -7.7%. [[IMMP]] -5.1%. [[MIND]] -4.6%. [[AMRN]] -4.1%. [[TLSA]] -3.2%. For further details see: OTIC, HLIT, VNET and TLSA among after-hours movers
Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...
Otonomy (OTIC) has priced its public offering of ~6.3M common shares at $2.25/share and, pre-funded warrants to purchase up to ~7.1M shares at $2.249/pre-funded warrant.Expected gross are ~$30.1M.Underwriters' over-allotment is an additional 2.01M shares. Cowen and Piper Sandler are acting as...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...